Autonomously AI for diabetic eye screening

The high-performance EyeArt AI algorithm automatically detects diabetic retinopathy quickly, accurately, and consistently, with higher sensitivity than an eye care expert trained in image grading.

EyeArt is intended to be used for:

• Detection and grading of DR according to ICDR scale (on eye level)
• Detection of DME
• Detection of glaucomatous optic nerve damage
• Detection of AMD

The EyeArt system is easy to use and with minimal training can be employed by nurses or technicians, enabling diabetic retinopathy screening at the point of care and eliminating an eye care specialist appointment just for screening.

The EyeArt AI Eye Screening System makes in-clinic, real-time diabetic retinopathy (DR) screening possible for primary care practices, diabetes centers and optometric offices by allowing physicians to quickly and accurately identify referable DR patients during a diabetic patient’s regular exam.

Eyenuk’s EyeArt® AI Eye Screening System for Diabetic Retinopathy has CE marking and is approved for sale in the EU as a Class IIb medical device.

Workflow with EyeArt

EyeArt supports both a decentral implementation pr. camera or enterprise installations across health regions, with an automated workflow that supports both quality control of images and automatic generation of a eyelevel result report.

Clinical Evidence

EyeArt has demonstrated high sensitivity (96% for more than mild DR and 97% for vision-threatening DR) and high specificity (88% for more than mild DR and 90% for vision-threatening DR) in a pivotal, prospective, multicenter clinical trial.

See here for more clinical studies and evidence:

https://www.eyenuk.com/en/clinical-evidence/eyeart/